BPC-157 FAQ: Direct, Cited Answers From the Record

What does BPC-157 do in the body?

It is described as a cytoprotective, pro-regenerative peptide whose animal-model effects are most consistently linked to angiogenesis via VEGFR2-Akt-eNOS signaling ^[3]. It up-regulates and internalizes the VEGFR2 receptor and modulates the nitric-oxide system. Human evidence is limited to three small pilot studies ^[10][11][14].

Is BPC-157 a growth hormone?

No. BPC-157 is a synthetic 15-amino-acid gastric pentadecapeptide, not a hormone. In tendon-fibroblast studies it is reported to up-regulate the growth-hormone receptor rather than act as growth hormone itself ^[3]. Its molecular weight is 1419.53 Da, far smaller than a protein hormone.

Does BPC-157 work immediately?

Pharmacokinetic work in rats and dogs reports a short elimination half-life of under 30 min ^[2], but healing outcomes in injury models develop over days of repeated dosing ^[1]. The two are different clocks: the molecule clears quickly while the tissue effect accrues. There is no validated human onset timeline.

How long does BPC-157 take to work?

In animal injury models, structural and functional improvements emerge over days of repeated dosing ^[1]. There is no validated human timeline. Reported plasma half-life is under 30 min in animals ^[2], so the molecule clears long before the tissue effect appears — the clock that matters is the healing one, and it is days, not minutes, in the models.

Can BPC-157 be taken orally?

It is called a stable gastric pentadecapeptide because it is reported to resist degradation in gastric juice, and rat gastric-ulcer work used intragastric dosing ^[4]. That stability is why oral routes are of research interest. Formal human oral pharmacokinetics are not established, so an oral route has no validated human basis.

Does oral BPC-157 work?

Oral and peroral routes have been used in animal cytoprotection studies, and reviews note interest in oral delivery owing to the gastric stability ^[4][11]. But there is no validated human oral efficacy or PK data. In the rat gastric-ulcer model, intramuscular dosing outperformed intragastric ^[4], so even in animals the oral route was not equivalent.

Can BPC-157 protect against drug or toxin damage?

In rodent models BPC-157 has been reported to counteract lithium-overdose toxicity ^[5] and to reduce distant-organ damage in liver, kidney and lung during acute pancreatitis ^[13]; 2025 reviews frame these as cytoprotection effects following intoxications ^[9]. All of it is preclinical. There is no human toxicity-treatment data, and none of this is antidote or interaction guidance.

Can BPC-157 heal arthritis?

An uncontrolled human case series reported reduced knee pain across several pain types after intra-articular BPC-157 injection ^[6], and rodent work shows tendon, ligament and bone healing. None of this is controlled evidence that BPC-157 treats arthritis; the case series had no comparator group, and arthritis is not an established indication.

How long should I stay on BPC-157?

There is no established human protocol or duration. The doses in the literature are animal, per-body-weight figures — around 10 microg/kg and 10 ng/kg in rodents ^[1] — and no validated human dosing or course length exists. Any specific duration circulating online is not grounded in the published evidence.

Is BPC-157 legal?

BPC-157 is not an FDA-approved drug, and FDA placed it in 503A Category 2 — bulk substances that may present significant safety risks — effective with its September 29, 2023 update, so it is not within FDA's enforcement-discretion policy for 503A compounding ^[17]. It is individually named on the July 23-24, 2026 PCAC agenda as under evaluation ^[16]. This is general information, not legal advice.

Can you get BPC-157 from a compounding pharmacy?

A 503A compounder may use a bulk substance only if it is eligible under the rules, and a Category 2 substance like BPC-157 is not eligible for routine 503A compounding while that status stands ^[16][17]. Legally compounded access generally requires a licensed-prescriber evaluation and a valid patient-specific prescription ^[16]. This page names no pharmacy and is not access advice.

What is the FDA 503A status of BPC-157?

FDA placed BPC-157 (the entries BPC-157 (free base) and BPC-157 acetate) in 503A Category 2, effective with its September 29, 2023 nominated-substances update, citing immunogenicity and peptide-characterization concerns ^[17]. Category 2 means it is not covered by FDA's enforcement-discretion policy for 503A compounding ^[16][17]. It is on the July 2026 PCAC agenda for evaluation only ^[16].

Does BPC-157 damage the liver?

A two-person IV safety pilot reported no measurable changes in hepatic biomarkers after infusion ^[10], and several rodent studies report hepatoprotective effects ^[13]. This is far too little human data to establish liver safety. No long-term human hepatic-safety data exist, so the question cannot be answered with confidence.

Is BPC-157 hard on the kidneys?

The two-participant IV safety pilot reported no measurable changes in renal biomarkers ^[10], and a rat pancreatitis study reported reduced kidney damage ^[13]. Long-term human renal-safety data do not exist. Two healthy adults in a single pilot cannot characterize kidney safety across a population.

Can BPC-157 mess with your heart?

In the small IV safety pilot, no cardiac-biomarker changes were measured after infusion of up to 20 mg in two adults ^[10]. Cardiac data otherwise come from rodent models. Human cardiovascular safety is unknown; a two-person pilot is not a cardiovascular safety study.

What happens when you stop taking BPC-157?

No withdrawal or discontinuation data exist in humans. The published work does not characterize what occurs after stopping, and claims about rebound effects are not evidence-based. Because the reported half-life is under 30 min in animals ^[2], the molecule itself clears quickly, but that says nothing about any downstream effect of stopping.

What should you not mix with BPC-157?

No human drug-interaction studies exist. Some rodent work reports BPC-157 counteracting toxicity from other agents, including a lithium-overdose model ^[5], but this is not interaction guidance and does not translate to human co-administration advice. The honest answer is that interactions are uncharacterized in people.

How does BPC-157 make you feel?

The small IV safety pilot described it as well tolerated with no adverse events ^[10], and some preclinical work reports effects on serotonin and dopamine systems ^[15]. Subjective human experiential data are essentially absent. There is no reliable account of how it "feels" because no study was designed to measure that.

Can BPC-157 help with weight loss?

No. Weight-loss claims are not supported by the published BPC-157 literature and should be treated skeptically. The research record is about cytoprotection and tissue repair ^[4][13], not metabolism or weight; any weight-loss marketing is unsupported by the evidence.

Can you drink alcohol while taking BPC-157?

There are no human studies on alcohol co-use. Rodent work has examined BPC-157 in alcohol-related liver and gastric models, but this does not provide human safety guidance for combining the two. The combination is uncharacterized in people, so no safe-use claim can be made.

Does BPC-157 build muscle?

Rodent studies report faster recovery from muscle crush injury, but there is no evidence that BPC-157 builds muscle in healthy humans; that claim is not supported by the literature. Faster repair of injured tissue in a model is a different thing from hypertrophy in a healthy person.

Does BPC-157 cause cancer?

This is unresolved. BPC-157 is pro-angiogenic in models ^[3], which is why the question is raised, but there are no human carcinogenicity data either way; the long-term safety profile is genuinely unknown ^[11]. Neither a reassurance nor an alarm is supported — the data to answer it do not exist.